CMS published plans Dec. 23 for its voluntary “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth” — or BALANCE — model. The announcement comes weeks following the White House’s agreements with Eli Lilly and Novo Nordisk to apply most-favored-nation…
Pharmacy
As we look ahead to 2026, the operational demands on 340B programs are increasing across every dimension. Between the implementation of the 340B Rebate Model pilot and Maximum Fair Price (MFP) covered entities (CEs) are entering a period where manual…
Becker’s asked pharmacy executives from hospitals and health systems across the U.S. to share how pharmacy c-suites will transform through 2030. The 11 executives featured in this article are all speaking at the Becker’s Healthcare Spring Chief Pharmacy Officer Summit,…
The FDA has approved Novo Nordisk’s pill version of Wegovy, making it the first oral GLP-1 receptor agonist therapy cleared for chronic weight management. The once-daily 25-milligram oral semaglutide is indicated to reduce excess body weight, maintain long-term weight loss…
Even as regulators are cracking down on pharmacy benefit managers, some payers have been leaning into their own businesses in 2025. Here are six payer moves indicating growing PBM interest: 1. Independent Health’s PBM subsidiary, Pharmacy Benefit Dimensions, is one…
Advertisement
A growing body of research suggests that older adults are discontinuing GLP-1 medications at high rates, The New York Times reported Dec. 21. Six things to know: 1. Sixty percent of Americans over age 65 with diabetes discontinued semaglutide within…
Samsung Biologics has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK, securing its first U.S.-based manufacturing site. The Rockville, Md., facility includes two current good manufacturing practice-compliant plants with a combined 60,000 liters of…
The Pharmacy Technician Certification Board has awarded a research grant to assess the feasibility of a nationwide mentorship program for certified pharmacy technicians. Researchers will use interviews and survey data to evaluate interest in a mentorship model, training needs and…
The FDA awarded two national priority review vouchers through its Commissioner’s National Priority Voucher pilot program on Dec. 19, bringing the total granted to 18. The latest vouchers were issued for enlicitide decanoate, an oral PCSK9 inhibitor aimed at lowering…
AstraZeneca will end U.S. commercial sales of Andexxa Dec. 22, citing safety concerns raised in postmarketing data and a recent trial, according to a Dec. 18 FDA news release. Andexxa, a recombinant factor Xa reversal agent, received accelerated approval in…